Farr Katherina P, Moses Daniel, Haghighi Koroush S, Phillips Phoebe A, Hillenbrand Claudia M, Chua Boon H
School of Clinical Medicine, Faculty of Medicine & Health, UNSW, Sydney, NSW 2052, Australia.
Graduate School of Biomedical Engineering, UNSW, Sydney, NSW 2052, Australia.
Cancers (Basel). 2022 May 21;14(10):2539. doi: 10.3390/cancers14102539.
Pancreatic cancer, one of the most lethal malignancies, is increasing in incidence. While survival rates for many cancers have improved dramatically over the last 20 years, people with pancreatic cancer have persistently poor outcomes. Potential cure for pancreatic cancer involves surgical resection and adjuvant therapy. However, approximately 85% of patients diagnosed with pancreatic cancer are not suitable for potentially curative therapy due to locally advanced or metastatic disease stage. Because of this stark survival contrast, any improvement in early detection would likely significantly improve survival of patients with pancreatic cancer through earlier intervention. This comprehensive scoping review describes the current evidence on groups at high risk for developing pancreatic cancer, including individuals with inherited predisposition, pancreatic cystic lesions, diabetes, and pancreatitis. We review the current roles of imaging modalities focusing on early detection of pancreatic cancer. Additionally, we propose the use of advanced imaging modalities to identify early, potentially curable pancreatic cancer in high-risk cohorts. We discuss innovative imaging techniques for early detection of pancreatic cancer, but its widespread application requires further investigation and potentially a combination with other non-invasive biomarkers.
胰腺癌是最致命的恶性肿瘤之一，其发病率正在上升。尽管在过去20年里，许多癌症的生存率有了显著提高，但胰腺癌患者的预后一直很差。胰腺癌的潜在治愈方法包括手术切除和辅助治疗。然而，由于局部晚期或转移性疾病阶段，约85%被诊断为胰腺癌的患者不适合进行潜在的治愈性治疗。由于这种明显的生存差异，早期检测方面的任何改善都可能通过早期干预显著提高胰腺癌患者的生存率。这篇全面的范围综述描述了目前关于胰腺癌高危人群的证据，包括具有遗传易感性、胰腺囊性病变、糖尿病和胰腺炎的个体。我们综述了目前聚焦于胰腺癌早期检测的成像模态的作用。此外，我们建议使用先进的成像模态在高危队列中识别早期、潜在可治愈的胰腺癌。我们讨论了用于早期检测胰腺癌的创新成像技术，但其广泛应用需要进一步研究，可能还需要与其他非侵入性生物标志物相结合。
